Qiagen N.V. Common Shares (QGEN)
Stock · NYSE · Health Care
$43.11as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$41.05
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About QGEN
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary samp…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 5,500
- Website
- www.qiagen.com/
Fundamentals
- 1-day range
- $43$43.99
- Market cap
- $8.72B
- P/E (trailing)
- 22.14
- P/E (forward)
- 16.52
- EPS (trailing)
- $1.89
- Dividend yield
- 0.81%
- Beta
- 0.62
- Avg. volume
- 2.95M
- Ex-dividend date
- July 7, 2026
- Dividend pay date
- July 14, 2026
52-week range
$32.53$57.82
Next earnings: November 4, 2026 · EPS estimate $0.62After Closeconfirmed
Forecasts
14 analyst ratings
Buy 55%
Hold 46%
Sell 0%
1-year price forecast
High
$50
+16.0%
Median
$46.5
+7.9%
Low
$40
-7.2%
Qiagen N.V. Common Shares Competitors
Chosen by industry and closest market cap.
- QGENQiagen N.V. Common Shares$43.12▼ 1.43%Market cap $8.72BP/E 22.14$32.53$57.82
- KYMRKymera Therapeutics Inc. Common Stock$118.08▼ 1.79%Market cap $8.25BP/E —$39.84$130.05
- HALOHalozyme Therapeutics Inc. Common Stock$105.33▼ 1.49%Market cap $9.76BP/E 27.63$61.23$109.66
- CRSPCRISPR Therapeutics AG Common Shares$57.69▼ 2.84%Market cap $4.78BP/E —$44.12$78.48
- ADPTAdaptive Biotechnologies Corporation Common Stock$25.19▼ 4.73%Market cap $3.70BP/E —$12$26.87
- RLAYRelay Therapeutics Inc. Common Stock$18.78▼ 3.30%Market cap $3.60BP/E —$3.5$21.27
- BEAMBeam Therapeutics Inc. Common Stock$29.31▼ 3.84%Market cap $2.67BP/E —$16.02$38.26
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| QGEN Qiagen N.V. Common Shares | $8.72B | 22.14 | $43.12 | ▼ 1.43% | $32.53$57.82 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.25B | — | $118.08 | ▼ 1.79% | $39.84$130.05 |
| HALO Halozyme Therapeutics Inc. Common Stock | $9.76B | 27.63 | $105.33 | ▼ 1.49% | $61.23$109.66 |
| CRSP CRISPR Therapeutics AG Common Shares | $4.78B | — | $57.69 | ▼ 2.84% | $44.12$78.48 |
| ADPT Adaptive Biotechnologies Corporation Common Stock | $3.70B | — | $25.19 | ▼ 4.73% | $12$26.87 |
| RLAY Relay Therapeutics Inc. Common Stock | $3.60B | — | $18.78 | ▼ 3.30% | $3.5$21.27 |
| BEAM Beam Therapeutics Inc. Common Stock | $2.67B | — | $29.31 | ▼ 3.84% | $16.02$38.26 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 10x Genomics Wins Patent Case Against Parse Biosciences As Jury Finds Willful Infringement And Awards $4.8M+ In Damages; Company To Seek Enhanced Damages, Fees And Permanent Injunctionbenzinga · 8/28/2026
- 4% Undervalued? Qiagen (QGEN) As Q2 Beat And FDA Clearance Lift The StoryYahoo · 8/14/2026
- Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip?Yahoo · 8/13/2026
- Strong Beats Mask Zillow’s (Z) Restructuring And HeadwindsYahoo · 8/13/2026
- Will FDA Clearance of QIAstat-Dx Bloodstream Panel Change Qiagen's (QGEN) Syndromic Testing Narrative?Yahoo · 8/13/2026
- Qiagen (QGEN) Q2 2026 Earnings Call TranscriptYahoo · 8/13/2026
- QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection PanelYahoo · 8/10/2026
- QIAGEN Says FDA Clears QIAstat-Dx BCID GPF Plus AMR Panel For Bloodstream InfectionsBenzinga · 8/10/2026
- Understanding Qiagen (QGEN) Reliance on International RevenueYahoo · 8/10/2026
See the full, filterable feed with live charts on the MarketWall dashboard.